Table 1. Demographic and clinical characteristics
| Infliximab | Etanercept | Adalimumab | Tocilizumab | |
|---|---|---|---|---|
| N=47 | N=17 | N=25 | N=18 | |
| Before HAM-D, mean (SD) | 6.1 (4.4) | 6.5 (4.8) | 4.8 (2.5) | 5.8 (4.1) |
| After HAM-D, mean (SD) | 4.0 (3.8) | 2.6 (2.8) | 4.4 (4.2) | 3.4 (3.7) |
| Before SDS, mean (SD) | 41.0 (9.9) | 42.4 (9.4) | 41.6 (10.6) | 38.8 (7.8) |
| After SDS, mean (SD) | 38.2 (10.7) | 36.2 (11.3) | 40.5 (11.5) | 37.9 (9.2) |
| ΔPhysical function, mean (SD) | 6.7 (15.3) | 12.1 (22.3) | 4.6 (15.9) | 5.5 (12.0) |
| ΔRole physical, mean (SD) | 8.6 (15.2) | 17.7 (16.9)ab | 1.8 (17.8) | 3.8 (14.3) |
| ΔBody pain, mean (SD) | 6.9 (10.1) | 12.8 (9.6)ac | 2.0 (9.3) | 6.5 (7.9) |
| ΔGeneral health, mean (SD) | 4.9 (8.3) | 8.9 (7.8) | 3.6 (9.6) | 5.1 (11.1) |
| ΔVitality, mean (SD) | 4.3 (10.6) | 9.6 (11.3)a | 1.6 (11.1) | 5.8 (10.4) |
| ΔSocial function, mean (SD) | 4.9 (13.0) | 14.8 (14.7)ab | 2.9 (15.7) | 2.6 (13.4) |
| ΔRole emotion, mean (SD) | 7.3 (17.8) | 12.2 (16.3)abc | Δ3.1 (12.2) | 1.2 (13.5) |
| ΔMental health, mean (SD) | 4.9 (9.1) | 7.1 (9.1)a | 0.32 (9.0) | 4.9 (15.5) |
ap<0.05 etanercept vs. adalimumab, bp<0.05 etanercept vs. tocilizumab, cp<0.05 infliximab vs. adalimumab.